Delayed risk stratification system in pT1aN0/Nx DTC patients treated without radioactive iodine
Open Access
- 1 October 2017
- journal article
- research article
- Published by Bioscientifica in Endocrine Connections
- Vol. 6 (7) , 522-527
Abstract
Purpose Delayed risk stratification (DRS) system by Momesso and coworkers was accepted by the American Thyroid Association as a diagnostic tool for the risk stratification of unfavorable clinical outcomes and to monitor the clinical outcomes of differentiated thyroid cancer (DTC) patients treated without radioactive iodine (RAI). The aim of this study was to evaluate the DRS system in patients with pT1aN0/Nx stage. Methods The study included 304 low-risk patients after thyroidectomy (n = 202) or lobectomy (n = 102) without RAI and were treated at a single center. The median age was 50.5 years, 91.1% were women and the median follow-up was 4 years. DRS of the treatment response was performed based on medical records and according to the criteria of Momesso and coworkers. Disease course (recurrence, death) and status (remission, persistent disease) on December 31, 2016 were evaluated. The relationship between unfavorable outcomes and the DRS system was evaluated. Results Response to initial therapy was excellent in 272 patients (89.5%), indeterminate in 31 (10.2%) and biochemical incomplete (increased TgAb levels) in one (0.3%). Two patients in the excellent response group experienced recurrence at 6 and 7 years of follow-up (after lobectomy). None of the patients with indeterminate and biochemical incomplete response developed structural disease, and none of the patients died during the follow-up. Conclusions The DRS system was not useful for predicting the risk of unfavorable clinical outcomes and cannot be used to personalize the monitoring method of the disease in patients at pT1aN0/Nx stage who are not treated with RAI.Keywords
This publication has 16 references indexed in Scilit:
- Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive IodineThe Journal of Clinical Endocrinology & Metabolism, 2016
- The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer RecurrencePLOS ONE, 2016
- The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid CancerPLOS ONE, 2015
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012Cancer Research and Treatment, 2015
- In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin ResponseThyroid®, 2011
- Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patientsEuropean Journal of Endocrinology, 2011
- The Most Commonly Occurring Papillary Thyroid Cancer in the United States Is Now a Microcarcinoma in a Patient Older than 45 YearsThyroid®, 2011
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging SystemThyroid®, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumEuropean Journal of Endocrinology, 2006